Contrary to an expected enhancement of antiviral signaling by p53, our study showed that both p53 and p53-CC inhibited type I IFN responses in cancer cells, but not in non-malignant human pancreatic ductal cells, which retained their resistance to all tested VSV recombinants. The gene discussed is TP53; the disease is cancer.